Global Plasma Protease C1-inhibitor Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug;

C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist.

By Dosage Form;

Lyophilized and Injectable.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn912836739 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Plasma Protease C1-inhibitor Market (USD Million), 2021 - 2031

In the year 2024, the Global Plasma Protease C1-inhibitor Market was valued at USD 6,283.82 million. The size of this market is expected to increase to USD 19,721.98 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 17.8%.

The global plasma protease C1-inhibitor market occupies a critical position within the realm of rare diseases and immunology, offering life-saving treatments for individuals afflicted by hereditary angioedema (HAE) and other related conditions. Plasma protease C1-inhibitor, a vital protein involved in regulating the body's immune response and inflammatory processes, serves as the cornerstone of therapy for these debilitating disorders.

The market for plasma protease C1-inhibitor products is propelled by a growing understanding of HAE and related diseases, coupled with advancements in biotechnology and pharmaceutical research. These innovations have led to the development of highly purified and recombinant forms of plasma protease C1-inhibitor, offering improved efficacy, safety, and convenience compared to earlier treatments.

Increasing awareness among healthcare professionals and patients about the impact of HAE on quality of life and the availability of effective treatments have driven demand for plasma protease C1-inhibitor therapies worldwide. This heightened awareness, coupled with improved diagnosis and treatment guidelines, has expanded the patient pool and fueled market growth.

The global plasma protease C1-inhibitor market is characterized by a competitive landscape, with several biopharmaceutical companies actively engaged in research, development, and commercialization of plasma-derived and recombinant C1-inhibitor products. These companies are focused on enhancing product efficacy, expanding indications, and addressing unmet needs in patient populations with HAE and related disorders.

The market is influenced by regulatory developments, reimbursement policies, and patient advocacy efforts aimed at improving access to plasma protease C1-inhibitor therapies. With ongoing advancements in biotechnology and healthcare delivery, the global plasma protease C1-inhibitor market is poised for continued expansion, offering hope and relief to individuals living with HAE and other rare diseases.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug
    2. Market Snapshot, By Dosage Form
    3. Market Snapshot, By Region
  4. Global Plasma Protease C1-inhibitor Market Trends
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Hereditary Angioedema (HAE)
        2. Rare Diseases
        3. Immunology
        4. Biotechnology Advancements
      2. Restraints
        1. Limited Access to Treatment
        2. High Treatment Costs
        3. Regulatory Hurdles
        4. Lack of Awareness among Healthcare Providers
      3. Opportunities
        1. Expanded Indications
        2. Emerging Markets
        3. Technological Advancements
        4. Patient Advocacy
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Plasma Protease C1-inhibitor Market, By Drug, 2021 - 2031 (USD Million)
      1. C1-inhibitors
      2. Kallikrein Inhibitor
      3. Selective Bradykinin B2 Receptor Antagonist
    2. Global Plasma Protease C1-inhibitor Market, By Dosage Form, 2021 - 2031 (USD Million)
      1. Lyophilized
      2. Injectable
    3. Global Plasma Protease C1-inhibitor Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia/New Zealand
        5. South Korea
        6. ASEAN
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. CSL Behring LLC
      2. Takeda Pharmaceutical Company Limited (Shire Pharmaceutical Holdings)
      3. Pharming Technologies B.V.
      4. KalVista Pharmaceuticals, Inc.
      5. BioCryst Pharmaceuticals
  7. Analyst Views
  8. Future Outlook of the Market